| Literature DB >> 30167299 |
Sara Shahrestani1, Hanh Minh Tran1, Henry C Pleass1,2, Wayne J Hawthorne1,2,3.
Abstract
BACKGROUND: Immunosuppression in transplant patients increases the risk of wound complications. However, an optimal surgical approach to kidney and pancreas transplantation can minimise this risk.Entities:
Keywords: BMI, Body mass index; CENTRAL, Cochrane register of randomized controlled trials; Complication; Hernia; Immunosuppression; MMF, Mycophenolate mofetil; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, Randomised controlled trial; SPK, Simultaneous pancreas-kidney transplantation; Transplant; Wound
Year: 2018 PMID: 30167299 PMCID: PMC6108074 DOI: 10.1016/j.amsu.2018.08.006
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Summary of studies considered in this systematic review and meta-analysis.
| Reference | Organ | Incision | Closure | Immunosuppression | Total Recipients | Hernia No. | Design |
|---|---|---|---|---|---|---|---|
| Mehrsai [ | Kidney | 230 | 1 | Retrospective | |||
| Sheriffdeen [ | Kidney | 481 | 3 | Prospective | |||
| Dean [ | Kidney | Pararectus | Single | Prednisone, MMF and 59 received tacrolimus while 64 received sirolimus | 123 | 8 | Prospective |
| Humar [ | Kidney | Hockey-stick | Fascial | Cyclosporine, azathioprine, and prednisone (MMF final year) | 2013 | 73 | Retrospective |
| Pliszczynski [ | Kidney | Cyclosporine with or without sirolimus | 593 | 154 | Retrospective | ||
| Nanni [ | Kidney | Hockey stick or oblique incision | Single | 100 | 10 | Retrospective | |
| Singh [ | Kidney | Cyclosporine, MMF, and prednisone | 68 | 3 | Retrospective | ||
| Mahdavi [ | Kidney | Paramedian incision | Fascial | Cyclosporine, azathioprine, and prednisolone (recently MMF) | 589 | 16 | Retrospective |
| Mazzucchi [ | Kidney | Rutherford-Morrison | Fascial | Cyclosporine, azathioprine, and MMF | 371 | 14 | Retrospective |
| Luc [ | Kidney | n/a | 61 | Retrospective | |||
| Neeff [ | Kidney | Rutherford-Morrison | Cyclosporine or tacrolimus, MMF, and prednisone | 100 | 4 | Retrospective | |
| Varga B [ | Kidney | Rutherford-Morrison | Fascial | MMF, prednisone and cyclosporine or tacrolimus | 1067 | 28 | Retrospective |
| Birolini [ | Kidney | Cyclosporine, azathioprine, and prednisone | 1685 | 19 | Retrospective | ||
| Knight [ | Kidney | Rutherford-Morrison | Fascial | Sirolimus, cyclosporine, and prednisone | 263 | 34 | Retrospective |
| Chang [ | Kidney | Midline laparotomy right or left lower quadrant | 3289 | 42 | Retrospective | ||
| Benavides [ | Kidney | Sirolimus, cyclosporine, and prednisone | 350 | 46 | Retrospective | ||
| Filocamo [ | Kidney | Midline and hockey-stick | 168 | 18 | Retrospective | ||
| Marconi [ | Kidney | 1233 | 29 | Retrospective | |||
| Ooms [ | Kidney | 1564 | 50 | Retrospective | |||
| Broggi [ | Kidney | Rutherford-Morrison | Odds ratios for single | Odds ratios for many combinations provided in text | 225 | 45 | Retrospective |
| Li [ | Kidney (1 SPK) | 2499 | 41 | Retrospective | |||
| Antonopoulos [ | Kidney and SPK | Rutherford-Morrison | Fascial | Cyclosporine, azathioprine/MMF, and prednisone | 462 | 13 | Retrospective |
| Smith [ | Kidney and SPK | 2, 742 | See note | Retrospective | |||
| Yannam [ | Kidney and Pancreas | n/a | 93 | Retrospective | |||
| Genzini [ | Pancreas | 171 | 4 | Retrospective | |||
| Piros [ | SPK | Midline | Fascial | Sirolimus, cyclosporine, and prednisone | 23 | 8 | Retrospective |
Data was presented in a form that we could not use for analysis.
Fig. 1CONSORT diagram of results at each stage of the search.
Newcastle-Ottawa Scale assessment of Quality of Individual studies.
| Selection | Comparability | Outcome | ||||||
|---|---|---|---|---|---|---|---|---|
| Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Assessment of outcome | Follow up was long enough for outcomes to occur | Adequacy of follow up of cohorts | ||
| Antonopoulos [ | * | * | * | * | * | * | * | * |
| Benavides [ | * | * | * | * | * | * | * | * |
| Birolini [ | * | * | * | * | * | * | * | * |
| Broggi [ | * | * | * | * | * | * | * | * |
| Chang [ | * | * | * | * | * | * | * | |
| Dean [ | * | * | * | * | ** | * | * | * |
| Filocamo [ | * | * | * | * | * | * | ||
| Genzini [ | * | * | * | * | * | * | * | |
| Humar [ | * | * | * | * | * | * | * | |
| Knight [ | * | * | * | * | * | * | * | * |
| Li [ | * | * | * | * | * | * | * | |
| Luc [ | * | * | * | * | * | * | ||
| Mahdavi [ | * | * | * | * | * | * | * | |
| Marconi [ | * | * | * | * | * | * | * | |
| Mazzucchi [ | * | * | * | * | * | * | * | * |
| Mehrsai [ | * | * | * | * | * | * | * | |
| Nanni [ | * | * | * | * | * | * | * | |
| Neeff [ | * | * | * | * | * | * | ||
| Oooms [ | * | * | * | * | * | * | ||
| Piros [ | * | * | * | * | * | * | * | * |
| Pliszczynski [ | * | * | * | * | * | * | * | |
| Sheriffdeen [ | * | * | * | * | * | |||
| Singh [ | * | * | * | ** | * | * | * | |
| Smith [ | * | * | * | * | * | * | * | * |
| Varga [ | * | * | * | * | * | * | * | |
| Yannam [ | * | * | * | * | * | * | ||
Fig. 2Forest plot of hernia rates in included studies of kidney and pancreas transplantation.
Fig. 3A) mean recipient age; B) mean recipient BMI and rate of incisional hernia formation in kidney and pancreas transplant recipients.
Fig. 4Immunosuppression and rate of incisional hernia formation in kidney and pancreas transplant recipients.
Fig. 5A; incision type (A: Rutherford-Morrison, B: Paramedian, C: Midline, D: Hockey-Stick) and B; closure type and rate of incisional hernia formation in kidney and pancreas transplant recipients.
Fig. 6Recurrence rate of an incisional hernia after open repair with and without mesh in kidney and pancreas transplant recipients.